{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:02:07Z","timestamp":1789556527192,"version":"build-2803163510"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"DOI":"10.1038\/s41577-026-01356-5","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:58:41Z","timestamp":1789549121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2533-644X","authenticated-orcid":false,"given":"Rafal","family":"Hanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-8347","authenticated-orcid":false,"given":"Robin","family":"Demuynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-2047","authenticated-orcid":false,"given":"Dmitri V.","family":"Krysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"1356_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2007.06.009","volume":"112","author":"R Pabst","year":"2007","unstructured":"Pabst, R. Plasticity and heterogeneity of lymphoid organs. What are the criteria to call a lymphoid organ primary, secondary or tertiary? Immunol. Lett. 112, 1\u20138 (2007).","journal-title":"Immunol. Lett."},{"key":"1356_CR2","doi-asserted-by":"publisher","first-page":"217491","DOI":"10.1016\/j.canlet.2025.217491","volume":"613","author":"X Cui","year":"2025","unstructured":"Cui, X. et al. Tertiary lymphoid structures as a biomarker in immunotherapy and beyond: advancing towards clinical application. Cancer Lett. 613, 217491 (2025).","journal-title":"Cancer Lett."},{"key":"1356_CR3","doi-asserted-by":"publisher","first-page":"1231315","DOI":"10.3389\/fimmu.2023.1231315","volume":"14","author":"L Esparcia-Pinedo","year":"2023","unstructured":"Esparcia-Pinedo, L., Romero-Laorden, N. & Alfranca, A. Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer. Front. Immunol. 14, 1231315 (2023).","journal-title":"Front. Immunol."},{"key":"1356_CR4","doi-asserted-by":"publisher","first-page":"101797","DOI":"10.1016\/j.smim.2023.101797","volume":"69","author":"C Cui","year":"2023","unstructured":"Cui, C., Craft, J. & Joshi, N. S. T follicular helper cells in cancer, tertiary lymphoid structures, and beyond. Semin. Immunol. 69, 101797 (2023).","journal-title":"Semin. Immunol."},{"key":"1356_CR5","doi-asserted-by":"publisher","first-page":"e1054598","DOI":"10.1080\/2162402X.2015.1054598","volume":"5","author":"A Hennequin","year":"2016","unstructured":"Hennequin, A. et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. OncoImmunology 5, e1054598 (2016).","journal-title":"OncoImmunology"},{"key":"1356_CR6","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","volume":"22","author":"DR Kroeger","year":"2016","unstructured":"Kroeger, D. R., Milne, K. & Nelson, B. H. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 22, 3005\u20133015 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1356_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","volume":"74","author":"J Goc","year":"2014","unstructured":"Goc, J. et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74, 705\u2013715 (2014).","journal-title":"Cancer Res."},{"key":"1356_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29753-z","volume":"13","author":"S Garaud","year":"2022","unstructured":"Garaud, S., Dieu-Nosjean, M.-C. & Willard-Gallo, K. T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy. Nat. Commun. 13, 2259 (2022).","journal-title":"Nat. Commun."},{"key":"1356_CR9","doi-asserted-by":"publisher","first-page":"e70063","DOI":"10.1111\/imr.70063","volume":"335","author":"SM Guillaume","year":"2025","unstructured":"Guillaume, S. M., Beccaria, C. G., Iannacone, M. & Linterman, M. A. Tertiary lymphoid structures across organs: context, composition, and clinical levers. Immunol. Rev. 335, e70063 (2025).","journal-title":"Immunol. Rev."},{"key":"1356_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1172\/JCI71611","volume":"124","author":"NH Ruddle","year":"2014","unstructured":"Ruddle, N. H. Lymphatic vessels and tertiary lymphoid organs. J. Clin. Invest. 124, 953\u2013959 (2014).","journal-title":"J. Clin. Invest."},{"key":"1356_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/ni1330","volume":"7","author":"DL Drayton","year":"2006","unstructured":"Drayton, D. L., Liao, S., Mounzer, R. H. & Ruddle, N. H. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7, 344\u2013353 (2006).","journal-title":"Nat. Immunol."},{"key":"1356_CR12","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1158\/0008-5472.CAN-11-0431","volume":"71","author":"L Martinet","year":"2011","unstructured":"Martinet, L. et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 71, 5678\u20135687 (2011).","journal-title":"Cancer Res."},{"key":"1356_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman, W. H. et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19, 441\u2013457 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1356_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12026-025-09595-9","volume":"73","author":"B Han","year":"2025","unstructured":"Han, B., Deng, J. & Fan, R. Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in lung adenocarcinoma. Immunol. Res. 73, 40 (2025).","journal-title":"Immunol. Res."},{"key":"1356_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"1356_CR16","doi-asserted-by":"publisher","first-page":"109422","DOI":"10.1016\/j.celrep.2021.109422","volume":"36","author":"AB Rodriguez","year":"2021","unstructured":"Rodriguez, A. B. et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36, 109422 (2021).","journal-title":"Cell Rep."},{"key":"1356_CR17","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/s42255-023-00908-6","volume":"5","author":"D Wu","year":"2023","unstructured":"Wu, D. et al. Proline uptake promotes activation of lymphoid tissue inducer cells to maintain gut homeostasis. Nat. Metab. 5, 1953\u20131968 (2023).","journal-title":"Nat. Metab."},{"key":"1356_CR18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-024-08426-5","volume":"638","author":"M Amisaki","year":"2025","unstructured":"Amisaki, M. et al. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Nature 638, 1076\u20131084 (2025).","journal-title":"Nature"},{"key":"1356_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.trecan.2022.12.007","volume":"9","author":"N Guti\u00e9rrez-Melo","year":"2023","unstructured":"Guti\u00e9rrez-Melo, N. & Baumjohann, D. T follicular helper cells in cancer. Trends Cancer 9, 309\u2013325 (2023).","journal-title":"Trends Cancer"},{"key":"1356_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-319-78127-3_4","volume":"1060","author":"CG Mueller","year":"2018","unstructured":"Mueller, C. G., Nayar, S., Campos, J. & Barone, F. Molecular and cellular requirements for the assembly of tertiary lymphoid structures. Adv. Exp. Med. Biol. 1060, 55\u201372 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1356_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/33340","volume":"392","author":"M Baggiolini","year":"1998","unstructured":"Baggiolini, M. Chemokines and leukocyte traffic. Nature 392, 565\u2013568 (1998).","journal-title":"Nature"},{"key":"1356_CR22","doi-asserted-by":"publisher","first-page":"e87680","DOI":"10.1172\/jci.insight.87680","volume":"1","author":"Y Sato","year":"2016","unstructured":"Sato, Y. et al. Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. JCI Insight 1, e87680 (2016).","journal-title":"JCI Insight"},{"key":"1356_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.molmed.2013.12.002","volume":"20","author":"H-J Anders","year":"2014","unstructured":"Anders, H.-J., Romagnani, P. & Mantovani, A. Pathomechanisms: homeostatic chemokines in health, tissue regeneration, and progressive diseases. Trends Mol. Med. 20, 154\u2013165 (2014).","journal-title":"Trends Mol. Med."},{"key":"1356_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/35018581","volume":"406","author":"KM Ansel","year":"2000","unstructured":"Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309\u2013314 (2000).","journal-title":"Nature"},{"key":"1356_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3727\/096368909X481782","volume":"19","author":"SY Rabbany","year":"2010","unstructured":"Rabbany, S. Y. et al. Continuous delivery of stromal cell-derived factor-1 from alginate scaffolds accelerates wound healing. Cell Transpl. 19, 399\u2013408 (2010).","journal-title":"Cell Transpl."},{"key":"1356_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1749-6632.1999.tb08460.x","volume":"872","author":"HE Broxmeyer","year":"1999","unstructured":"Broxmeyer, H. E. et al. Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Ann. N. Y. Acad. Sci. 872, 142\u2013163 (1999).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1356_CR27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1126\/science.1185837","volume":"328","author":"JD Shields","year":"2010","unstructured":"Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M. & Swartz, M. A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328, 749\u2013752 (2010).","journal-title":"Science"},{"key":"1356_CR28","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).","journal-title":"Science"},{"key":"1356_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1359-6101(98)00025-2","volume":"10","author":"R Hofmeister","year":"1999","unstructured":"Hofmeister, R. et al. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor. Rev. 10, 41\u201360 (1999).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"1356_CR30","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.4049\/jimmunol.0902999","volume":"184","author":"C Deteix","year":"2010","unstructured":"Deteix, C. et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J. Immunol. 184, 5344\u20135351 (2010).","journal-title":"J. Immunol."},{"key":"1356_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"1356_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","volume":"8","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L. et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J. Immunother. Cancer 8, e000337 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1356_CR33","doi-asserted-by":"publisher","first-page":"200333","DOI":"10.1016\/j.tvr.2025.200333","volume":"20","author":"G Cao","year":"2025","unstructured":"Cao, G., Ding, C., Dai, J. & Qiu, X. Oncolytic virus and immunogenic cell death in cancer therapy. Tumour Virus Res. 20, 200333 (2025).","journal-title":"Tumour Virus Res."},{"key":"1356_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cytogfr.2013.05.001","volume":"24","author":"O Kepp","year":"2013","unstructured":"Kepp, O. et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor. Rev. 24, 311\u2013318 (2013).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"1356_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02380-0","volume":"24","author":"Q Wang","year":"2025","unstructured":"Wang, Q., Yu, Y., Zhuang, J., Liu, R. & Sun, C. Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment. Mol. Cancer 24, 178 (2025).","journal-title":"Mol. Cancer"},{"key":"1356_CR36","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. The cGAS\u2013STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548\u2013569 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1356_CR37","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson, N. & Ablasser, A. The cGAS\u2013STING pathway and cancer. Nat. Cancer 3, 1452\u20131463 (2022).","journal-title":"Nat. Cancer"},{"key":"1356_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon, J. & Bakhoum, S. F. The cytosolic DNA-sensing cGAS\u2013STING pathway in cancer. Cancer Discov. 10, 26\u201339 (2020).","journal-title":"Cancer Discov."},{"key":"1356_CR39","doi-asserted-by":"publisher","first-page":"118790","DOI":"10.1016\/j.biopha.2025.118790","volume":"193","author":"E Alipour-Khezri","year":"2025","unstructured":"Alipour-Khezri, E., Moqadami, A., Zununi Vahed, S. & Barzegari, A. Cytosolic DNA sensing pathway in senescence and aging: underlying mechanisms and targeted interventions. Biomed. Pharmacother. 193, 118790 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"1356_CR40","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1021\/acs.chemrev.1c00750","volume":"122","author":"KM Garland","year":"2022","unstructured":"Garland, K. M., Sheehy, T. L. & Wilson, J. T. Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy. Chem. Rev. 122, 5977\u20136039 (2022).","journal-title":"Chem. Rev."},{"key":"1356_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-026-08607-2","author":"Q Li","year":"2026","unstructured":"Li, Q. et al. The cGAS\u2013STING pathway in cancer: friend or foe. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-026-08607-2 (2026).","journal-title":"Cell Death Dis."},{"key":"1356_CR42","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.ccell.2022.11.005","volume":"40","author":"Z Ma","year":"2022","unstructured":"Ma, Z. et al. Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell 40, 1550\u20131565.e7 (2022).","journal-title":"Cancer Cell"},{"key":"1356_CR43","doi-asserted-by":"publisher","first-page":"15408","DOI":"10.1073\/pnas.1512832112","volume":"112","author":"O Demaria","year":"2015","unstructured":"Demaria, O. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl Acad. Sci. USA 112, 15408\u201315413 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1356_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07645-2","volume":"24","author":"L Wang","year":"2026","unstructured":"Wang, L. et al. Cell-type specific activation of the cGAS\u2013STING pathway in tumor immunotherapy: mechanisms and therapeutic implications. J. Transl. Med. 24, 43 (2026).","journal-title":"J. Transl. Med."},{"key":"1356_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.20892\/j.issn.2095-3941.2022.0750","volume":"20","author":"Q Wu","year":"2023","unstructured":"Wu, Q., Leng, X. & Xu, P. Intercellular transmission of cGAS\u2013STING signaling in cancer. Cancer Biol. Med. 20, 93\u201397 (2023).","journal-title":"Cancer Biol. Med."},{"key":"1356_CR46","doi-asserted-by":"publisher","first-page":"2451207","DOI":"10.1002\/eji.202451207","volume":"54","author":"AL Calvanese","year":"2024","unstructured":"Calvanese, A. L. et al. Sustained innate interferon is an essential inducer of tertiary lymphoid structures. Eur. J. Immunol. 54, 2451207 (2024).","journal-title":"Eur. J. Immunol."},{"key":"1356_CR47","doi-asserted-by":"publisher","first-page":"e001906","DOI":"10.1136\/jitc-2020-001906","volume":"9","author":"M Chelvanambi","year":"2021","unstructured":"Chelvanambi, M., Fecek, R. J., Taylor, J. L. & Storkus, W. J. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J. Immunother. Cancer 9, e001906 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1356_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54294-y","volume":"15","author":"A Iannuzzo","year":"2024","unstructured":"Iannuzzo, A. et al. Autoinflammatory patients with Golgi-trapped CDC42 exhibit intracellular trafficking defects leading to STING hyperactivation and ER stress. Nat. Commun. 15, 9940 (2024).","journal-title":"Nat. Commun."},{"key":"1356_CR49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2015.00603","volume":"6","author":"CV Carman","year":"2015","unstructured":"Carman, C. V. & Martinelli, R. T lymphocyte\u2013endothelial interactions: emerging understanding of trafficking and antigen-specific immunity. Front. Immunol. 6, 603 (2015).","journal-title":"Front. Immunol."},{"key":"1356_CR50","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","volume":"40","author":"Y Hua","year":"2022","unstructured":"Hua, Y. et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. Cancer Cell 40, 1600\u20131618 (2022).","journal-title":"Cancer Cell"},{"key":"1356_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10456-021-09792-8","volume":"24","author":"L Blanchard","year":"2021","unstructured":"Blanchard, L. & Girard, J.-P. High endothelial venules (HEVs) in immunity, inflammation and cancer. Angiogenesis 24, 719\u2013753 (2021).","journal-title":"Angiogenesis"},{"key":"1356_CR52","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.it.2022.07.002","volume":"43","author":"B Hussain","year":"2022","unstructured":"Hussain, B. et al. High endothelial venules as potential gateways for therapeutics. Trends Immunol. 43, 728\u2013740 (2022).","journal-title":"Trends Immunol."},{"key":"1356_CR53","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2326-6066.CIR-21-0369","volume":"10","author":"J Sawada","year":"2022","unstructured":"Sawada, J. et al. Molecular signature of tumor-associated high endothelial venules that can predict breast cancer survival. Cancer Immunol. Res. 10, 468\u2013481 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"1356_CR54","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/cas.14023","volume":"110","author":"S Kuwabara","year":"2019","unstructured":"Kuwabara, S. et al. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Cancer Sci. 110, 1853\u20131862 (2019).","journal-title":"Cancer Sci."},{"key":"1356_CR55","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ccell.2023.02.002","volume":"41","author":"G Vella","year":"2023","unstructured":"Vella, G., Hua, Y. & Bergers, G. High endothelial venules in cancer: regulation, function, and therapeutic implication. Cancer Cell 41, 527\u2013545 (2023).","journal-title":"Cancer Cell"},{"key":"1356_CR56","doi-asserted-by":"publisher","first-page":"1302751","DOI":"10.3389\/fimmu.2024.1302751","volume":"15","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma. Front. Immunol. 15, 1302751 (2024).","journal-title":"Front. Immunol."},{"key":"1356_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/cr.2010.161","volume":"21","author":"VF-S Shih","year":"2011","unstructured":"Shih, V. F.-S., Tsui, R., Caldwell, A. & Hoffmann, A. A single NF\u03baB system for both canonical and non-canonical signaling. Cell Res. 21, 86\u2013102 (2011).","journal-title":"Cell Res."},{"key":"1356_CR58","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1038\/s41590-025-02259-8","volume":"26","author":"J Sawada","year":"2025","unstructured":"Sawada, J. et al. Simultaneous STING and lymphotoxin-\u03b2 receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity. Nat. Immunol. 26, 1766\u20131780 (2025).","journal-title":"Nat. Immunol."},{"key":"1356_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8114","volume":"6","author":"JD Peske","year":"2015","unstructured":"Peske, J. D. et al. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6, 7114 (2015).","journal-title":"Nat. Commun."},{"key":"1356_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao, L. et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal. Transduct. Target. Ther. 9, 225 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1356_CR61","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3389\/fimmu.2016.00477","volume":"7","author":"F Barone","year":"2016","unstructured":"Barone, F. et al. Stromal fibroblasts in tertiary lymphoid structures: a novel target in chronic inflammation. Front. Immunol. 7, 477 (2016).","journal-title":"Front. Immunol."},{"key":"1356_CR62","doi-asserted-by":"crossref","unstructured":"Anshu, Shantikumar V., N. & Sreeja, R. Pleiotropic and multicellular roles of lymphotoxin beta receptor in solid tumor immunity and therapeutic targeting. Front. Immunol. 17, 1693507 (2026).","DOI":"10.3389\/fimmu.2026.1693507"},{"key":"1356_CR63","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00262-025-04183-0","volume":"74","author":"C Tan","year":"2025","unstructured":"Tan, C. et al. Dynamic remodeling of tertiary lymphoid structures in response to cancer therapy: a recent review. Cancer Immunol. Immunother. CII 74, 313 (2025).","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"1356_CR64","doi-asserted-by":"publisher","first-page":"13490","DOI":"10.1073\/pnas.1905301116","volume":"116","author":"S Nayar","year":"2019","unstructured":"Nayar, S. et al. Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proc. Natl Acad. Sci. USA 116, 13490\u201313497 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1356_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2024.09.005","volume":"106\u2013107","author":"F Chen","year":"2024","unstructured":"Chen, F. et al. DAMPs in immunosenescence and cancer. Semin. Cancer Biol. 106\u2013107, 123\u2013142 (2024).","journal-title":"Semin. Cancer Biol."},{"key":"1356_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adk2612","volume":"9","author":"R Zhao","year":"2024","unstructured":"Zhao, R. et al. cGAS-activated endothelial cell\u2013T cell cross-talk initiates tertiary lymphoid structure formation. Sci. Immunol. 9, eadk2612 (2024).","journal-title":"Sci. Immunol."},{"key":"1356_CR67","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"1356_CR68","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2006.06.016","volume":"25","author":"Y Lee","year":"2006","unstructured":"Lee, Y. et al. Recruitment and activation of naive T cells in the islets by lymphotoxin \u03b2 receptor-dependent tertiary lymphoid structure. Immunity 25, 499\u2013509 (2006).","journal-title":"Immunity"},{"key":"1356_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202516348","volume":"65","author":"D Qu","year":"2025","unstructured":"Qu, D. et al. Biodegradable nano-regulator reprograms glioblastoma immunosuppression: pyroptosis\u2013metabolism\u2013immunity crosstalk for cascading immune activation. Angew. Chem. Int. Ed. Engl. 65, e16348 https:\/\/doi.org\/10.1002\/anie.202516348 (2025).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1356_CR70","doi-asserted-by":"publisher","first-page":"e011563","DOI":"10.1136\/jitc-2025-011563","volume":"13","author":"N Porciello","year":"2025","unstructured":"Porciello, N. et al. Spatial transcriptomics highlights B cells as key contributors to a complete and durable response to chemo-immunotherapy in a patient with resectable NSCLC. J. Immunother. Cancer 13, e011563 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1356_CR71","doi-asserted-by":"publisher","first-page":"1221532","DOI":"10.3389\/fimmu.2023.1221532","volume":"14","author":"RA O\u2019Connor","year":"2023","unstructured":"O\u2019Connor, R. A., Martinez, B. R., Koppensteiner, L., Mathieson, L. & Akram, A. R. Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta. Front. Immunol. 14, 1221532 (2023).","journal-title":"Front. Immunol."},{"key":"1356_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52153-4","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma. Nat. Commun. 15, 7713 (2024).","journal-title":"Nat. Commun."},{"key":"1356_CR73","doi-asserted-by":"publisher","first-page":"1616247","DOI":"10.3389\/fimmu.2025.1616247","volume":"16","author":"K Zhai","year":"2025","unstructured":"Zhai, K., Xie, R., Ru, K. & Zhao, M. Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy. Front. Immunol. 16, 1616247 (2025).","journal-title":"Front. Immunol."},{"key":"1356_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55430-4","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy. Nat. Commun. 16, 44 (2025).","journal-title":"Nat. Commun."},{"key":"1356_CR75","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.semcancer.2025.05.003","volume":"113","author":"G Roscigno","year":"2025","unstructured":"Roscigno, G. et al. The potential application of stroma modulation in targeting tumor cells: focus on pancreatic cancer and breast cancer models. Semin. Cancer Biol. 113, 151\u2013175 (2025).","journal-title":"Semin. Cancer Biol."},{"key":"1356_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-28296-9","volume":"15","author":"L Hu","year":"2025","unstructured":"Hu, L. et al. Prognostic impact of tertiary lymphoid structures and cancer-associated fibroblasts in hepatocellular carcinoma with portal vein tumor thrombus. Sci. Rep. 15, 45161 (2025).","journal-title":"Sci. Rep."},{"key":"1356_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56275-1","volume":"16","author":"A Perucca","year":"2025","unstructured":"Perucca, A. et al. Micro immune response on-chip (MIRO) models the tumour-stroma interface for immunotherapy testing. Nat. Commun. 16, 1279 (2025).","journal-title":"Nat. Commun."},{"key":"1356_CR78","doi-asserted-by":"publisher","first-page":"100546","DOI":"10.1016\/j.medj.2024.10.023","volume":"6","author":"F Peyraud","year":"2025","unstructured":"Peyraud, F. et al. Tertiary lymphoid structures and cancer immunotherapy: from bench to bedside. Med. 6, 100546 (2025).","journal-title":"Med."},{"key":"1356_CR79","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s12672-024-01556-2","volume":"15","author":"C Yu","year":"2024","unstructured":"Yu, C. et al. Research trends, hotspots and future directions of tertiary lymphoid structures in cancer: a comprehensive informatics analysis and visualization study. Discov. Oncol. 15, 665 (2024).","journal-title":"Discov. Oncol."},{"key":"1356_CR80","doi-asserted-by":"publisher","first-page":"e006667","DOI":"10.1136\/jitc-2023-006667","volume":"11","author":"W Xu","year":"2023","unstructured":"Xu, W. et al. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma. J. Immunother. Cancer 11, e006667 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1356_CR81","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.ajpath.2015.03.012","volume":"185","author":"AR Noort","year":"2015","unstructured":"Noort, A. R. et al. Tertiary lymphoid structures in rheumatoid arthritis: NF-\u03baB\u2013inducing kinase\u2013positive endothelial cells as central players. Am. J. Pathol. 185, 1935\u20131943 (2015).","journal-title":"Am. J. Pathol."},{"key":"1356_CR82","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.molmed.2024.10.014","volume":"31","author":"C Yang","year":"2025","unstructured":"Yang, C., Cai, Y.-X., Wang, Z.-F., Tian, S.-F. & Li, Z.-Q. Tertiary lymphoid structures in the central nervous system. Trends Mol. Med. 31, 509\u2013521 (2025).","journal-title":"Trends Mol. Med."},{"key":"1356_CR83","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/mi.2009.111","volume":"2","author":"PJL Lane","year":"2009","unstructured":"Lane, P. J. L. et al. Lymphoid tissue inducer cells: bridges between the ancient innate and the modern adaptive immune systems. Mucosal Immunol. 2, 472\u2013477 (2009).","journal-title":"Mucosal Immunol."},{"key":"1356_CR84","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fimmu.2012.00024","volume":"3","author":"PJL Lane","year":"2012","unstructured":"Lane, P. J. L., Gaspal, F. M., McConnell, F. M., Withers, D. R. & Anderson, G. Lymphoid tissue inducer cells: pivotal cells in the evolution of cd4 immunity and tolerance? Front. Immunol. 3, 24 (2012).","journal-title":"Front. Immunol."},{"key":"1356_CR85","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bj.2020.12.003","volume":"44","author":"SA van de Pavert","year":"2021","unstructured":"van de Pavert, S. A. Lymphoid tissue inducer (LTi) cell ontogeny and functioning in embryo and adult. Biomed. J. 44, 123\u2013132 (2021).","journal-title":"Biomed. J."},{"key":"1356_CR86","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1084\/jem.20100052","volume":"208","author":"M Lochner","year":"2011","unstructured":"Lochner, M. et al. Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma T and LTi cells. J. Exp. Med. 208, 125\u2013134 (2011).","journal-title":"J. Exp. Med."},{"key":"1356_CR87","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell 42, 1370\u20131385.e9 (2024).","journal-title":"Cancer Cell"},{"key":"1356_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04017-6","volume":"21","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi, L., Kepp, O., Hett, E., Kroemer, G. & Marincola, F. M. Immunogenic cell death in cancer: concept and therapeutic implications. J. Transl. Med. 21, 162 (2023).","journal-title":"J. Transl. Med."},{"key":"1356_CR89","doi-asserted-by":"publisher","first-page":"1396349","DOI":"10.3389\/fimmu.2024.1396349","volume":"15","author":"F Naessens","year":"2024","unstructured":"Naessens, F. et al. CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity. Front. Immunol. 15, 1396349 (2024).","journal-title":"Front. Immunol."},{"key":"1356_CR90","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1356_CR91","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/imr.13271","volume":"321","author":"C Galassi","year":"2024","unstructured":"Galassi, C., Klapp, V., Yamazaki, T. & Galluzzi, L. Molecular determinants of immunogenic cell death elicited by radiation therapy. Immunol. Rev. 321, 20\u201332 (2024).","journal-title":"Immunol. Rev."},{"key":"1356_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003430","volume":"9","author":"R Demuynck","year":"2021","unstructured":"Demuynck, R., Efimova, I., Naessens, F. & Krysko, D. V. Immunogenic ferroptosis and where to find it? J. Immunother. Cancer 9, e003430 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1356_CR93","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361 (2007).","journal-title":"Nat. Med."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01356-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01356-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01356-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:03:24Z","timestamp":1789553004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01356-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":93,"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01356-5","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"21 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}